This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sumner, W. E. Articles by Franceschi, D. Search for Related Content PubMed PubMed Citation Articles by Sumner, W. E., III Articles by Franceschi, D.

Results of 23,810 Cases of Ductal Carcinoma-in-situ

Division of Surgical Oncology, Department of Surgery, Sylvester Comprehensive Cancer Center, Room 3550, University of Miami, Miami, Florida 33136

Correspondence: Address correspondence and reprint requests to: Dido Franceschi, MD; E-mail: dfrances{at}med.miami.edu

Background: Screening mammography has increased the number of patients diagnosed with ductal carcinoma-in-situ (DCIS) in the past 20 years. The Florida Cancer Data System is the largest single source incident cancer registry in the United States. We analyzed this registry to determine the changing incidence and treatment patterns for DCIS.

Methods: Patients with DCIS from 1981 to 2001 were identified. Age-adjusted rate, descriptive statistics, and incidence of future DCIS and invasive breast cancer were calculated.

Results: A total of 23,810 DCIS patients were identified. The age-adjusted rate of DCIS has risen from 2.4 to 27.7 per 100,000 women between 1981 and 2001. Median age was 64 years; 85% of patients were white, 6.6% African American, and 7.5% Hispanic. Median tumor size was .9 cm. Forty-seven percent of patients had breast-conserving therapy (BCT). Half of the 53% of patients undergoing mastectomy underwent a modified radical mastectomy. Eight percent received no surgical treatment. Sentinel lymph node biopsy was used in 2.7% of patients who underwent a mastectomy. After BCT, 37.5% received adjuvant radiotherapy, and only 13% were treated with hormonal therapy.

Conclusions: The incidence of DCIS has risen dramatically with the advent of screening mammography. Increasing numbers of these patients are treated with BCT, although a large proportion are still treated with mastectomy, in some cases combined with axillary dissection. Sentinel lymph node biopsy and tamoxifen are important components of therapy, the use of which is slowly increasing in the treatment of DCIS.

Key Words: DCIS • Breast cancer • Intraductal carcinoma • Mastectomy • Breast conservation

This article has been cited by other articles:

				D. Grady, J. A. Cauley, M. J. Geiger, M. Kornitzer, L. Mosca, P. Collins, N. K. Wenger, J. Song, J. Mershon, E. Barrett-Connor, et al. Reduced Incidence of Invasive Breast Cancer With Raloxifene Among Women at Increased Coronary Risk J Natl Cancer Inst, June 18, 2008; 100(12): 854 - 861. [Abstract] [Full Text] [PDF]

				H. Medina-Franco, S. Soto-Germes, J. L. Ulloa-Gomez, C. Romero-Trejo, N. Uribe, C. A. Ramirez-Alvarado, and C. Robles-Vidal Radiofrequency Ablation of Invasive Breast Carcinomas: A Phase II Trial Ann. Surg. Oncol., June 1, 2008; 15(6): 1689 - 1695. [Abstract] [Full Text] [PDF]

				E. S. Hwang, D. L. Miglioretti, R. Ballard-Barbash, D. L. Weaver, K. Kerlikowske, and for the National Cancer Institute Breast Cancer Su Association between Breast Density and Subsequent Breast Cancer Following Treatment for Ductal Carcinoma In situ Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2587 - 2593. [Abstract] [Full Text] [PDF]